Acrivon CEO reports RSU tax share withholding

Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen.

Rhea-AI Filing Summary

Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen. The company withheld 14,265 shares of common stock at $1.53 per share to cover mandatory taxes due on vested restricted stock units, rather than an open-market sale. After this withholding, Dr. Blume-Jensen directly holds 2,080,204 common shares. The filing also notes 314,127 common shares held indirectly in spousal accounts shared between Dr. Blume-Jensen and co-founder and EVP Dr. Kristina Masson, with each spouse disclaiming beneficial ownership beyond their economic interest.

Insider Trade Summary

Exercise Price or Tax Liability: 14,265 shares

Exercise Price or Tax Liability 2 txns

Insider Blume-Jensen Peter, Masson Kristina

Role President and CEO | EVP - Business Operations

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	14,265	$1.53	$22K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,080,204 shares (Direct); Common Stock — 314,127 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. F2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
3. F3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report in this Form 4?

Acrivon Therapeutics reported a tax-withholding disposition, where 14,265 common shares were withheld from President and CEO Dr. Peter Blume-Jensen upon RSU vesting to satisfy mandatory tax obligations, rather than being sold in the open market.

How many Acrivon Therapeutics (ACRV) shares does the CEO hold after this transaction?

Following the tax-withholding transaction, CEO Dr. Peter Blume-Jensen directly holds 2,080,204 common shares of Acrivon Therapeutics. This reflects his ownership after the issuer withheld 14,265 shares to cover taxes on vested restricted stock units.

Was the Acrivon Therapeutics (ACRV) Form 4 transaction an open-market sale?

No. The Form 4 shows a Form F tax-withholding disposition, meaning 14,265 shares were withheld by Acrivon Therapeutics to pay required taxes on RSU vesting, not actively sold by the insider into the market.

What indirect Acrivon Therapeutics (ACRV) share holdings are disclosed for the insiders?

The filing discloses 314,127 common shares held indirectly in spousal accounts between CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other’s holdings except for their pecuniary, or economic, interest.

Who are the insiders involved in this Acrivon Therapeutics (ACRV) Form 4?

The Form 4 involves Dr. Peter Blume-Jensen, Acrivon’s President and CEO, and Dr. Kristina Masson, co-founder and EVP – Business Operations. It details a tax-related share withholding and their direct and indirect common stock holdings with spousal disclosure language.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/21/2026		F(1)		14,265	D	$1.53	2,080,204	D(2)
Common Stock								314,127	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Blume-Jensen Peter

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

Masson Kristina

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Business Operations

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

2. These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

3. These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

	/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen	02/24/2026
	/s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.